Peritoneal metastases from rare ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC)
There are limited treatment options and no consensus on the management of advanced rare ovarian malignancies. Rare ovarian malignancies can present with peritoneal metastases (PM), featuring a similar presentation to more common ovarian subtypes. Cytoreductive surgery and hyperthermic intraperitonea...
Main Authors: | Falla-Zuniga Luis Felipe, Sardi Armando, King Mary Caitlin, Lopez-Ramirez Felipe, Barakat Philipp, Nieroda Carol, Diaz-Montes Teresa, Gushchin Vadim |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2023-12-01
|
Series: | Pleura and Peritoneum |
Subjects: | |
Online Access: | https://doi.org/10.1515/pp-2023-0019 |
Similar Items
-
Current clinical practices of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
by: Acs Miklos, et al.
Published: (2024-03-01) -
Advances in the Treatment of Colorectal Cancer with Peritoneal
Metastases: A Focus on Cytoreductive Surgery and Hyperthermic Intraperitoneal
Chemotherapy
by: Youngbae Jeon, et al.
Published: (2023-12-01) -
The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis
by: Guyu Zhang, et al.
Published: (2019-04-01) -
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Mitomycin C Used for Colorectal Peritoneal Carcinomatosis
by: Seung Jae Roh, et al.
Published: (2020-02-01) -
High intra-abdominal pressure during hyperthermic intraperitoneal chemotherapy (HIPEC) following cytoreductive surgery (CRS) for peritoneal surface malignancies
by: Louis Choon Kit Wong, et al.
Published: (2022-12-01)